Evaluation of sofosbuvir plus daclatasvir combination for hepatitis C virus treatment

被引：0
|
作者：
Moron Romero, Rocio [1 ]
Diaz, Xando [1 ]
del Carmen Gonzalez, Maria [1 ]
Rodriguez, Alejandro [1 ]
Casas, Inmaculada [1 ]
Cabeza, Jose [1 ]
机构：
[1] Complejo Hosp Univ Granada, Pharm, Granada, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2017年 / 39卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT028
引用
收藏
页码：331 / 331
页数：1
相关论文
共 50 条
  • [1] Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
    Saadoun, David
    Ferfar, Yasmina
    Bouyer, A. S.
    Alric, Laurent
    Hezode, Christophe
    Ahmed, S. N. Si
    Musset, L.
    Pernot, Luc De Saint Martin
    Pol, S. N.
    Larrey, Dominique
    Poynard, T.
    Cacoub, Patrice
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C
    Rivero-Juarez, Antonio
    Brieva, Teresa
    Frias, Mario
    Rivero, Antonio
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (09) : 901 - 910
  • [3] Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
    Joharji, H.
    Alkortas, D.
    Ajlan, A.
    Devol, E.
    Ahmed, M.
    Al-Khail, F. Aba
    Elsiesy, H.
    Alsebayel, M.
    Alashgar, H.
    Alquaiz, M.
    Alhamoudi, W.
    Almoshishir, A.
    Aljedai, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 624 - 624
  • [4] Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis
    Ismail, Waleed A.
    Yousef, Ayman E.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (08) : 1025 - 1029
  • [5] Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus.
    Joharji, H.
    Al-Jedai, A.
    Alkortas, D.
    Ajlan, A.
    Devol, E.
    Ahmed, M.
    Al-Khail, F. Aba
    El-Siesy, H.
    Al-Sebayel, M.
    Al-Ashgar, H.
    Al-Quaiz, M.
    Alhomodi, W.
    Aloubal, A.
    Almohishir, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 970 - 971
  • [6] Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
    Sperl, Jan
    Frankova, Sona
    Kreidlova, Miluse
    Merta, Dusan
    Tothova, Monika
    Spicak, Julius
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 733 - 738
  • [7] Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection
    Bourliere, Marc
    Adhoute, Xavier
    Ansaldi, Christelle
    Oules, Valerie
    Benali, Souad
    Portal, Isabelle
    Castellani, Paul
    Halfon, Philippe
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (12) : 1483 - 1494
  • [8] Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection
    Llenas-Garcia, Jara
    Padilla, Sergio
    Masia, Mar
    Gutierrez, Felix
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018, 36 (07): : 457 - 457
  • [9] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [10] Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection
    Brieva, Teresa
    Rivero, Antonio
    Rivero-Juarez, Antonio
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (04) : 483 - 490
12345